AtriCure Reports First Quarter 2016 Financial Results

  • Revenue of $35.9 million – up 20.3% as reported, 20.4% constant
  • U.S. sales of $28.3 million – up 23.3%
  • International sales of $7.7 million – up 10.1% as reported, 10.9%
    constant currency

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced first quarter 2016 financial results.

“We are pleased to report first quarter results which reflect solid
operational and commercial execution. Performance in the quarter was
again marked by continued growth from U.S. customers, and we are
reiterating our guidance of 25% top line growth for 2016,” said Mike
Carrel, President and Chief Executive Officer of AtriCure. “We are also
pleased to have strengthened our balance sheet through the term loan
with Silicon Valley Bank which, coupled with initiatives underway,
strengthen our confidence in our ability to reach profitability in 2018.”

First Quarter 2016 Financial Results

Revenue for the first quarter of 2016 was $35.9 million, an increase of
$6.1 million or 20.3% (20.4% on a constant currency basis), compared to
first quarter 2015 revenue. Domestic revenue increased 23.3% to $28.3
million, driven by strong sales of ablation-related open-heart products,
ablation-related minimally invasive products, and AtriClip products.
International revenue was $7.7 million, an increase of $0.7 million or
10.1% (10.9% on a constant currency basis). International revenue growth
was driven primarily by increases in product sales in Japan, China, and
France, across all applicable product lines.

Gross profit for the first quarter of 2016 was $25.9 million compared to
$21.7 million for the first quarter of 2015. Gross margin for the first
quarter of 2016 and 2015 was 72.1% and 72.7%, respectively.

Operating expenses for the first quarter of 2016 increased 31.5%, or
$8.5 million, compared to the first quarter of 2015. The increase in
operating expenses was driven primarily by an increase in selling,
clinical, product development, marketing and training expenses, with
most of these areas impacted by the changes in our operating structure
to support our acquisition of nContact in late 2015.

Loss from operations for the first quarter of 2016 was $9.4 million,
compared to $5.1 million for the first quarter of 2015. Adjusted EBITDA,
a non-GAAP measure, was a loss of $4.4 million for the first quarter of
2016, compared to a $2.1 million loss for the first quarter of 2015. Net
loss per share was $0.31 for the first quarter of 2016 and $0.19 for the
first quarter of 2015.

2016 Financial Guidance

Management projects 2016 revenue growth of approximately 25% over full
year 2015 at current exchange rates.

Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the
range of $14 to $15 million for 2016 as the Company continues to make
strategic investments to drive the long-term growth plan, including
several clinical trials, modest expansion of the U.S. field sales team,
and ongoing product development efforts. In terms of EPS, this EBITDA
range translates into a loss of between $1.12 and $1.22. Significant
improvements in the adjusted EBITDA loss are expected for 2017, turning
to a positive adjusted EBITDA for 2018.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, April 28, 2016 to discuss its first quarter 2016 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at
You may also access this call through an operator by calling (855)
307-9214 for domestic callers and (330) 863-3275 for international
callers using conference ID number 84690180.

The webcast will be available on AtriCure’s website and a telephonic
replay of the call will be available through May 5, 2016. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. The conference ID number is 84690180.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that is indicated for
the occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. AtriCure recently acquired nContact, a leader in minimally
invasive technology for epicardial ablation. nContact’s mission is to
transform the underserved arrhythmia population through a
multidisciplinary epicardial-endocardial ablation approach. Afib affects
more than 33 million people worldwide. For more information visit or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements that address activities,
events or developments that AtriCure expects, believes or anticipates
will or may occur in the future, such as earnings estimates (including
projections and guidance), other predictions of financial performance,
launches by AtriCure of new products and market acceptance of AtriCure’s
products. Forward-looking statements are based on AtriCure’s experience
and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many
of which are beyond AtriCure’s control. These risks and uncertainties
include the rate and degree of market acceptance of AtriCure’s products,
AtriCure’s ability to develop and market new and enhanced products,
AtriCure’s ability to retain and attract key employees, the timing of
and ability to obtain and maintain regulatory clearances and approvals
for its products, the timing of and ability to obtain reimbursement of
procedures utilizing AtriCure’s products, AtriCure’s ability to continue
to be in compliance with applicable U.S. federal and state and foreign
government laws and regulations, AtriCure’s ability to consummate
acquisitions or, if consummated, to successfully integrate acquired
businesses into AtriCure’s operations, AtriCure’s ability to recognize
the benefits of acquisitions, including potential synergies and cost
savings, failure of an acquisition or acquired company to achieve its
plans and objectives generally, risk that proposed or consummated
acquisitions may disrupt operations or pose difficulties in employee
retention or otherwise affect financial or operating results, AtriCure’s
ability to raise the capital that may be required to accomplish the
foregoing, competition from existing and new products and procedures,
including the development of drug or catheter-based technologies, or
AtriCure’s ability to effectively react to other risks and uncertainties
described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, fluctuations in exchange
rates for future sales denominated in foreign currency, which represent
a majority of AtriCure’s sales outside of the United States, reliance on
third party manufacturers and suppliers, litigation or other
proceedings, government regulation and stock price volatility. AtriCure
does not guarantee any forward-looking statement, and actual results may
differ materially from those projected. AtriCure undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements
prepared in accordance with accounting principles generally accepted in
the United States of America, or GAAP, AtriCure uses certain non-GAAP
financial measures in this release as supplemental financial metrics.
Non-GAAP financial measures provide an indication of performance
excluding certain items. Management believes that in order to properly
understand short-term and long-term financial trends, investors may wish
to consider the impact of these excluded items in addition to GAAP
measures. The excluded items vary in frequency and/or impact on our
continuing operations and management believes that the excluded items
are typically not reflective of our ongoing core business operations.
Further, management uses results of operations before these excluded
items as a basis for its strategic planning. The non-GAAP financial
measures used by AtriCure may not be the same or calculated the same as
those used by other companies. Reconciliations of the non-GAAP financial
measures used in this release to the most comparable GAAP measures for
the respective periods can be found in tables later in this release.
Non-GAAP financial measures have limitations as analytical tools and
should not be considered in isolation or as a substitute for AtriCure’s
financial results prepared and reported in accordance with GAAP.

(In Thousands, Except Per Share Amounts)
Three Months Ended March 31,
2016 2015
Domestic Revenue:
Open-heart ablation $ 13,968 $ 12,354
Minimally invasive ablation 6,725 4,347
AtriClip   6,848     5,503  
Total ablation and AtriClip 27,541 22,204
Valve tools   731   719  
Total domestic 28,272 22,923
International Revenue:
Open-heart ablation 4,472 4,216
Minimally invasive ablation 2,164 1,968
AtriClip   865     671  
Total ablation and AtriClip 7,501 6,855
Valve tools   167     108  
Total international 7,668 6,963
Total revenue 35,940 29,886
Cost of revenue   10,026     8,151  
Gross profit 25,914 21,735
Operating expenses:
Research and development expenses 8,563 5,609
Selling, general and administrative expenses   26,770     21,270  
Total operating expenses   35,333     26,879  
Loss from operations (9,419 ) (5,144 )
Other expense, net   (300 )   (116 )
Loss before income tax expense (9,719 ) (5,260 )
Income tax expense (benefit) 5 6
Net loss $ (9,724 ) $ (5,266 )
Basic and diluted net loss per share $ (0.31 ) $ (0.19 )
Weighted average shares used in computing net loss per share:
Basic and diluted   31,358     27,069  
(In Thousands)
March 31, December 31,
2016 2015
Current assets:
Cash, cash equivalents, and short-term investments $ 23,324 $ 34,578
Accounts receivable, net 19,446 19,409
Inventories 19,015 17,659
Other current assets   3,608     3,106  
Total current assets 65,393 74,752
Property and equipment, net 31,155 31,279
Long-term investments 6,150 7,706
Goodwill and intangible assets, net 158,621 159,032
Other noncurrent assets   391     323  
Total assets $ 261,710   $ 273,092  
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities $ 25,732 $ 31,138
Other current liabilities and current maturities of capital leases   462     450  
Total current liabilities 26,194 31,588
Capital leases 13,592 13,710
Other noncurrent liabilities   40,897     41,109  
Total liabilities 80,683 86,407
Stockholders’ equity:
Common stock 33 32
Additional paid-in capital 356,638 352,900
Accumulated other comprehensive loss (284 ) (611 )
Accumulated deficit   (175,360 )   (165,636 )
Total stockholders’ equity   181,027     186,685  
Total liabilities and stockholders’ equity $ 261,710   $ 273,092  
(In Thousands)
Three Months Ended March 31,
2016 2015
Cash flows from operating activities:
Net loss $ (9,724 ) $ (5,266 )

Adjustments to reconcile net loss to net cash used in operating

Share-based compensation expense 2,842 1,724
Depreciation and amortization of intangible assets 2,211 1,311
Amortization of deferred financing costs 15 16
Loss on disposal of property and equipment 141 57
Realized (gain) loss from foreign exchange on intercompany
(5 ) 251
Amortization/accretion on investments 56 184
Change in allowance for doubtful accounts 100
Changes in operating assets and liabilities
Accounts receivable 30 (2,685 )
Inventories (1,232 ) (1,104 )
Other current assets (439 ) (779 )
Accounts payable and accrued liabilities (4,535 ) (2,807 )
Other non-current assets and liabilities   (291 )   28  
Net cash used in operating activities (10,931 ) (8,970 )
Cash flows from investing activities:
Purchases of available-for-sale securities (6,086 )
Sales and maturities of available-for-sale securities 9,800 11,899
Purchases of property and equipment (2,804 ) (1,434 )
Increases in property under build-to-suit obligation   (1,822 )
Net cash provided by investing activities 6,996 2,557
Cash flows from financing activities:
Payments on debt and capital leases (107 ) (14 )
Increases in build-to-suit obligation 1,822
Proceeds from stock option exercises 1,896 516
Shares repurchased for payment of taxes on stock awards (999 ) (503 )
Net cash provided by financing activities 790 1,821
Effect of exchange rate changes on cash and cash equivalents   149     (233 )
Net (decrease) increase in cash and cash equivalents (2,996 ) (4,825 )
Cash and cash equivalents – beginning of period   23,764     28,384  
Cash and cash equivalents – end of period $ 20,768   $ 23,559  
Supplemental cash flow information:
Cash paid for interest $ 244 $ 2
Cash paid for income taxes
Noncash investing and financing activities:
Accrued purchases of property and equipment 243 751
Assets acquired through capital lease 36
(In Thousands)
Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA)
Three Months Ended March 31,
2016 2015
Net loss, as reported $ (9,724 ) $ (5,266 )
Income tax expense 5 6
Other expense, net (a) 300 116
Depreciation and amortization expense 2,211 1,311
Share-based compensation expense   2,842     1,724  
Non-GAAP adjusted loss (adjusted EBITDA) $ (4,366 ) $ (2,109 )
Three Months Ended March 31,
2016 2015
(a) Other includes:
Net interest expense (income) $ 220 $ (25 )
Grant income (35 )
Loss due to exchange rate fluctuation 80 163
Non-employee stock option expense       13  
Other expense, net $ 300   $ 116  


AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice
President and Chief Financial Officer
Relations Contact

Gilmartin Group
Lynn Pieper, 415-937-5402